INTRODUCTION
============

Hematopoietic stem cell transplantation (HSCT) has become a common procedure of therapy for patients with hematological malignancies and many other life threatening blood disorders. However, viral and fungal infections associated with the severe immunoablative conditioning used prior to HSCT still represent a major challenge ([@B26]; [@B45]). One approach to address this barrier is to use reduced intensity conditioning (RIC). HSCT following RIC relies on non-myeloablative preparatory regimen that spares a substantial level of the host immunity and thus reduce transplant related mortality (TRM) by both improving post-transplant immune reconstitution and reducing the toxicity associated with the conditioning agents ([@B8]; [@B20]). RIC was first developed to enable allogeneic HSCT in patients with advanced hematological malignancies who cannot withstand myeloablative conditioning because of age and/or performance status. However, using such "safer " RIC protocols also enable the use of HSCT in patients with non-malignant disorders, associated with longer life expectancy. In these patients the aim of the conditioning prior to the allogeneic HSCT is merely to support sustained donor cell's engraftment for correction of the disease ([@B46]; [@B42]), or, as demonstrated in limited number of patients, for the induction of donor chimerism, as a platform for tolerance induction as prelude to organ transplantation ([@B21]; [@B44]). Nevertheless, currently used RIC protocols are still relatively aggressive and therefore it is highly desirable to develop "safer " preparative regimen protocols that selectively achieve a state of donor-specific unresponsiveness without compromising the overall immune response.

THE VETO CONCEPT
================

One way to achieve a state of donor-specific tolerance uses donor cells endowed with veto activity. The term "veto, " coined in 1980 by Miller ([@B27]), relates to the ability of cells to specifically delete T cells directed against antigens (Ags) of the veto cells themselves, but not against third-party Ag ([@B30]; [@B11]). The suppression of effector T cells directed against the veto cells is both Ag-specific and major histocompatibility complex (MHC) restricted, resulting from the unique manner by which the veto cell kills its target. Thus, veto activity results from unidirectional recognition of the veto cell by the responding T cell, but not vice versa. Therefore, the recognizing T cell, the T cell receptor (TCR) of which is directed against the MHC of the veto cell, is killed upon binding to its veto target, due to exchange of signals allowed following this interaction. Hence, the use of donor veto cells capable of specifically eliminating only the host anti-donor T cell clones that mediate the transplant rejection while sparing other T cells that can persist and fight infectious pathogens, could offer an effective modality for the induction of transplantation tolerance.

VETO ACTIVITY OF BONE-MARROW CELLS
==================================

Initially, veto activity was described for cells within the spleen of athymic nude mice ([@B27]). Based on this initial observation, various cell types have been shown to mediate veto activity including T lymphocytes, natural killer cells, and dendritic cells. A very strong veto activity was documented for CD8^+^ cytotoxic T cell (CTL) lines or clones ([@B15]; [@B12]; [@B10]) and direct comparison of the veto reactivity of various cell types revealed that CTLs have the strongest *in vitro* veto effect ([@B36]).

In the context of bone-marrow transplantation (BMT), cells in murine BM and in T cell colonies grown from such BM were shown to mediate veto activity *in vitro* ([@B29]) and un-separated donor BM was shown to specifically reduce the frequency of anti-donor CTLs in grafted mice ([@B49]). However, this *in vivo* tolerizing activity of the BM cells could be attributed to T cells which reside within the BM. These T cells, while potentially mediating beneficial veto activity, also cause a severe multi-system graft versus host disease (GVHD). Early attempts to avoid GVHD risk and to apply T cell-depleted BMT (TDBMT) in leukemia patients indeed revealed that this benefit of GVHD prevention is offset by increased risk for graft rejection, due to absence of donor T cells within the graft ([@B17]; [@B22]).

However, veto activity could be also assigned to non-T cells within the BM. For example, a series of studies by the group of Judy Thomas described potent veto activity of cells within the CD8^+^CD16^+^DR^-^ subset in the BM of rhesus macaque primates ([@B47]; [@B4]). CD8 surface expression was shown to play a pivotal role in the tolerogenic effect of these BM cells. Thus, these studies demonstrated that CD8 crosslinking following interaction with donor-reactive CTL precursors (CTLp), elicits upregulation of transforming growth factor-β1 (TGF-β1) and Fas ligand (FasL) by these donor BM cells, leading to clonal deletion of the donor-reactive CTLp ([@B4]; [@B13]).

Another example of marked clinical relevance is the demonstration by [@B34] that human hematopoietic CD34^+^ progenitors are endowed with marked veto activity (**Figure [1](#F1){ref-type="fig"}**). Explaining in part how "megadose " of purified CD34^+^ cells enables to overcome rejection in recipients of three HLA-loci mismatched (haploidentical) HSCT while avoiding the threat of GVHD ([@B5],[@B6]; [@B40]). Interestingly, [@B18] demonstrated that this veto activity is mediated through a TNF-α based mechanism. In addition, [@B19] demonstrated that veto activity is not only mediated directly by the infused CD34^+^ cells but also by their CD33^+^ progeny, which lose this tolerizing activity upon completion of maturation, at the level of CD14^+^ monocytes or CD13^+^ neutrophils. Furthermore, preliminary results suggest that BM-derived immature dendritic cells, previously shown to induce immune tolerance, exhibit marked veto activity on CD8 T cells, in addition to the non-specific suppression of CD4 T cells mediated by the NO system ([@B51]). Finally, NK cells which were shown to exhibit veto activity upon activation with IL-2, develop and appear early during the post-transplant period ([@B9]; [@B36]).

![**The regulatory activity of CD34 cells: evidence for target specificity**. The average CTL response (SD) in the presence (black bars) or absence (white bars) of CD34^+^ cells at a veto-to-responder cell ratio of 0.5. The veto effect was tested by a limiting dilution assay as follows: Equal numbers (1 × 10^6^/ml) of responder cells and irradiated allogeneic stimulator cells from the donor of the CD34 cells and a third-party donor were co-cultured for 5 days. The responder cells were then cultured again for 7 days under limiting dilution, and the CTL activity was determined by ^51^Cr-release assay. Data represent the average ± SD of 11 independent experiments using different donor and third-party pairs. A significant difference (*p* \< 0.001 on *t*-test compared with control cultures without CD34 cells) between control cultures and those including CD34 cells was found upon stimulation against donor cells ([@B34]).](fimmu-03-00093-g001){#F1}

Thus, based on these observations, the following working hypothesis can be suggested to explain how megadose of CD34^+^ cells can overcome rejection in human recipients of haploidentical HSCT. Upon administration of purified CD34^+^ cells, the graft supporting veto activity is initially mediated directly by the infused CD34^+^ cells, and subsequently by the CD33^+^ progeny of these cells which grow exponentially within the first few days post-transplant. This second phase of differentiating veto cells also includes CD11c+ immature dendritic cells and other graft facilitating cells. Clearly, the number of all these tolerizing cell types emerging after transplantation is proportional to the number of CD34^+^cells infused. The increased engraftment of megadose of HSCT is therefore greatly dependent not only on the ability of the initial inoculums of the CD34^+^ cells to veto anti-donor T cells, but also on their ability to seed the BM and to generate as rapidly as possible the second or third derivatives which are required to complete the eradication of host anti-donor T cells.

THE USE OF VETO CD8^+^ CTLs IN HSCT
===================================

As described above, the use of purified megadose of CD34^+^ HSCT has enabled haploidentical transplantation in leukemia patients and was the first demonstration of the potent clinical potential of donor veto cells. However, this approach is currently limited to supra-lethal myeloablative and highly immunosuppressive conditioning protocols ([@B26]). Indeed, studies in non-human primates revealed that any significant reduction of the conditioning, to levels acceptable for elderly patients or for patients with non-malignant disorders, would require veto inducing CD34^+^ stem cell numbers which cannot be realistically collected from human donors (Gan et al., unpublished results). Therefore, other populations of veto cells could have a crucial role in supporting and promoting successful engraftment of purified stem cell transplantation under relatively safer RIC.

As outlined above, CD8^+^ CTLs were shown *in vitro* to exhibit the strongest veto reactivity ([@B36]). Previous insights on the veto mechanism of CD8^+^ veto CTLs, combining anti-CD8 blockade and FasL-mutated veto cells, have suggested that co-expression of CD8 and FasL is required for the veto activity of these cells ([@B38],[@B36]). Such a mechanism involves initial recognition of the veto cell by the TCR of the effector T cells, leading to expression of Fas by the effector T cell upon activation, and thereby enabling Fas--FasL mediated apoptosis to take place, once inhibitory molecules such as FLICE-inhibitory protein (FLIP) are down regulated in the effector cell ([@B41]). In addition, the interaction between CD8 on veto CTL and the MHC class I alpha3 domain on the effector cell, is associated with phosphorylation of MEK/ERK in the latter cell, and with a significant reduction of X-linked inhibitor of apoptosis protein (XIAP) levels which, in turn, enables even more potent triggering of Fas--FasL mediated apoptosis in the recognizing effector cell **Scheme [1](#F3){ref-type="fig"}** [@B38]). More recent results have indicated that veto activity exhibited by CTLs can also be mediated by an additional perforin based mechanism ([@B28]). However, despite their potent veto activity, CD8^+^ CTLs cannot be used for "safe " tolerance induction in allogeneic HSCT because of their marked GVH reactivity.

![**Veto-based deletion of host anti-donor CD8 T cell clones by veto CTL**. CD8-MHC class I engagement induces pERK, which is associated with reduction of XIAP (apoptosis inhibitor) levels, thereby enabling Fas--FasL apoptosis to take place. Figure taken from [@B38].](fimmu-03-00093-g003){#F3}

One approach for generating veto CTLs with reduced GVHD reactivity has been described by a series of studies by D. H. Fowler ([@B16]; [@B14]; [@B25]).

In these studies, it was demonstrated that by using CD3/CD28 particles under IL-2-, IL-7-, and IL-4-containing medium, veto CTLs with Tc2 phenotype can be generated. These cells were shown to abrogate murine BM rejection with reduced GVHD.

We have previously described an alternative approach to generate CTLs with highly reduced GVH reactivity by means of stimulation against third-party stimulators in the absence of exogenous cytokines, followed by further *ex vivo* expansion using third-party stimulators and IL-2 ([@B7]). This approach was based on the observation that only activated CTLp are capable of surviving the cytokine deprivation in the primary culture, and that these anti-third-party clones further expand throughout the culture. These anti-third-party CTLs indeed were shown to be depleted of GVHD while supporting BM engraftment in murine models. In accordance with the veto concept, this tolerizing effect of the CTLs was found to be H-2 specific. Thus, a CTL line originating from a strain other than that of the BM donor failed to prevent graft rejection ([@B7]). Importantly, anti-third-party veto CTLs, upon adoptive transfer into TDBMT recipient mice, were shown to eliminate not only host anti-donor naïve cells, but also host anti-donor memory cells ([@B35]). Memory T cells, derived from prior exposure to alloantigen or generated by heterologous immunity or lymphopenia-induced proliferation, are believed to be an important part of the barrier preventing the translation of tolerance induction protocols from inbred rodent strains to the clinic ([@B33]; [@B1]; [@B50]). Therefore, the ability of veto CTLs to overcome memory T cells-mediated rejection could be highly important for their action in clinical settings. Furthermore, a recent study of [@B31] propose that veto CTL can also effectively promote B cell tolerance. Thus, in this study the authors demonstrated that murine CD8^+^ CTLs, in addition to their renowned veto activity upon recognizing T cells, can also induce Ag-specific elimination of recognizing B cells, both *in vitro* and *in vivo* and thus veto CTLs may selectively overcome both cellular and humoral graft rejection.

Nevertheless, despite all these important attributes of the veto CD8^+^ CTLs, their *in vivo* activity was shown to be markedly inferior compared to that exhibited *in vitro*, requiring the administration of large number of CTLs in conjunction with the immunosuppressive drug rapamycin in order to efficiently overcome TDBMT rejection in murine models ([@B7]). The discrepancy between the CTLs veto activity *in vitro* and *in vivo* could be explained when considering two limitations of the veto cells: first, the veto activity is mediated through cell to cell contact and, second, host T cells are prone to veto mainly in a window of opportunity of up to 48 h after their activation, thus, once these host T cells develop into mature effector T cells, veto cells can no longer exert their effect ([@B2]). Therefore, while *in vitro* the veto CTLs are directly plated with their cognate targets, upon infusion *in vivo* the veto CTLs need to co-localize with the host T cells within the first 48 h of the rejection process, or else their effect will be hampered. Indeed, we recently demonstrated that CTLs attained upon long *ex vivo* culture in the presence of IL-2 exhibit a migration pattern different from the one displayed by naive host T cells thereby precluding their co-localization. Thus, while naïve host T cells home efficiently to the lymph nodes (LNs) of BMT recipient mice, the veto CTLs are excluded from the LNs and tend to localize in peripheral sites ([@B32]).

CD8^+^ T CELLS WITH CENTRAL MEMORY PHENOTYPE FOR INDUCING POTENT *IN VIVO* VETO ACTIVITY
========================================================================================

In order to improve the LNs homing potential of anti-third-party CD8^+^ veto cells we developed a new protocol, using IL-15, that favor the induction of central memory phenotype in anti-third-pary CD8^+^ T cells ([@B32]). Central memory T cells (Tcm) express the LN homing receptors CD62L and CCR7 ([@B43]) and similarly to naive T cells, localize to the T cell area of all secondary lymphoid organs ([@B48]). Indeed, we demonstrated that these *ex vivo* induced anti-third-party Tcm, in contrast to anti-third-party CTLs, home to LNs of BMT recipients, where they co-localize with the recipient's endogenous host T cells. Moreover, the Tcm displayed strong proliferation at the early post-transplant period and subsequently persisted *in vivo* for more than 1 year post-BMT, in line with their memory phenotype ([@B32]). Most importantly, we demonstrated that Tcm derived from (host × donor)F1 mice can specifically and efficiently delete *in vivo* host TCR-transgenic T cells carrying a TCR transgene with anti-donor specificity. In accordance with the veto concept, this efficient *in vivo* deletion of anti-donor host T cells, found to be mediated by apoptosis, did not occur when "non-specific " Tcm, not expressing the donor H-2 haplotype, were used (**Figure [2](#F2){ref-type="fig"}**). Thus, murine Tcm perform *in vivo* veto activity, efficiently deleting host T cells only when the host T cells recognize antigens on the Tcm, and not by a non-specific general immunosuppressive effect. Taken together, all these attributes of the Tcm were shown to translate into improved efficacy in overcoming T cell mediated rejection of murine TDBMT, thereby enabling high survival rate and long-term donor chimerism, without causing GVHD. Thus, adoptive transfer of anti-third-party Tcm, in the absence of rapamycin treatment significantly abolished host T cells-mediated rejection of fully mismatched Nude-BM. This is in sharp contrast to anti-third-party CTLs, which fail to enable engraftment unless administered in higher numbers and in conjunction with rapamycin treatment ([@B7]; [@B32]). We concluded therefore that by generating anti-third-party CD8^+^ cells with a central memory phenotype we were able to dramatically enhance their tolerizing veto activity *in vivo*.

![**Anti-third-party Tcm are endowed with potent *in vivo* veto activity**. **(A,B)** Lethally irradiated C57BL/6 (H-2^b^) mice received 1 × 10^5^ CD8^+^ purified TCR-transgenic 2c cells (carrying TCR with anti H-2^d^ specificity) and 5 × 10^5^ irradiated BALB/c (H-2^d^) splenocytes. The following day, the mice were transplanted with 1 × 10^6^ C57BL/6-NUDE BM cells or received, in addition, 5 × 10^6^ "specific, " derived from CB6 (H-2^bd^, black bars), or "non-specific " , derived from C57BL/6 (H-2^b^, gray bars) anti-third-party Tcm. Recipients were sacrificed 8 days post-transplant, their spleens were harvested, and the deletion of anti-donor 2c T cells was monitored by FACS. **(A)** Representative result demonstrating the level of surviving (7AAD^-^) 2c cells in the absence (left panel, "2c alone " ) or presence of "specific " Tcm (right panel "2c + specific Tcm " ). **(B)** Quantification of results demonstrating efficient inhibition of the 2c cells only by "specific " and not by "non-specific " "Tcm. " Data represent average ± SD of percent inhibition from at least 10 animals in each group, pooled from two independent experiments. **(C,D)** *In vivo* model was established as in **(A,B)**, but 5 × 10^5^ purified CD8^+^ 2c cells and 2.5 × 10^6^ irradiated BALB/c splenocytes were administrated. Recipients were sacrificed 8 days post-transplant, their spleens were harvested and FACS analysis of Annexin V levels on living (7AAD^-^) CD8^+^1B2+ 2c cells was conducted. **(C)** Representative result demonstrating apoptosis induction upon anti-donor 2c cells by the Tcm as evident by Annexin V levels on 2c cells in the absence (left panel, "2c alone " ) or presence of "specific " Tcm (right panel, "2c + specific Tcm " ). **(D)** Quantification of results measuring Annexin V levels on the 2c cells following interactions with "specific " and "non-specific " "Tcm. " The figure shows that Apoptosis was induced only by the "specific " Tcm. Data present average ± SD of percent Annexin V levels in at least four animals from each group, in one representative experiment, out of three performed. \*\**p* \< 0.01, \*\*\**p* \< 0.001 ([@B32]).](fimmu-03-00093-g002){#F2}

TCR-INDEPENDENT KILLING OF MALIGNANT B CELLS BY CD8^+^ VETO CELLS
=================================================================

A second objective which could be attained by administration of donor-derived activated CD8^+^ T cells in the context of HSCT is related to the ability of these cells to control residual hematological malignancies. Considering that GVL is generally associated with GVHD it was surprising that autologous or allogeneic human and murine anti-third-party veto CD8^+^ T cells, markedly depleted of GVH reactivity, exhibit vigorous responses against different B cell malignancies ([@B3]; [@B23]). The killing of B cell tumors by anti-third-party CTLs was shown to involve a unique TCR-independent two steps mechanism. First, long-lasting conjugates are formed between the CTL and the tumor cell. These conjugates are rapidly formed through binding of ICAM1 on tumor cells by LFA-1 expressed on the veto CTL. Second, a slower process of MHC class I-dependent apoptosis is mediated by binding of the MHC class I α2/3 constant region on the tumor cells to the CD8 molecule on the CTL membrane ([@B3]; [@B23]). Likewise, recent results from our laboratory indicate that murine anti-third-party veto Tcm can also efficiently eliminate murine B cell lymphoma *in vivo*, through a similar TCR-independent mechanism ([@B24]). Hence, such single agent veto cell therapy has the potential to have a double benefit in the context of HSCT, namely, promoting and supporting HSCT engraftment through specific tolerizing veto activity while mediating effective anti-cancer response, in the absence of GVHD. Translation of this therapy, optimizing protocols for the generation of human anti-third-party Tcm is now in progress and clinical evaluation will commence in the near future in patients with B cell malignancies.

CONCLUDING REMARKS
==================

Donor derived veto cells represent an attractive and effective modality for the induction of specific tolerance toward donor Ags. This approach has been already demonstrated in patients by using megadose of purified veto CD34^+^ stem cells, that can overcome the host's residual immunity surviving the myeloablative conditioning and enable engraftment of HSCT across major genetic barriers without the severe threat of GVHD. However, the number of veto CD34^+^ cells that can be harvested is insufficient for overcoming the large numbers of host T cells remaining after RIC. Therefore, combining megadose of CD34^+^ HSCT with other GVHD-depleted veto cells, potentially anti-third-party CD8^+^ Tcm, could enable facilitation of engraftment of HSCT under RIC without the adverse complication of GVHD-producing T cells and without the need for deleterious post-transplant GVHD prophylaxis. It is hoped that this approach could extend the use of HSCT to elderly patients with B cell malignancies who cannot tolerate intensive protocols and to a variety of patients with non-malignant disorders, associated with longer life expectancy, in whom the current TRM associated with HSCT may not be ethically justified.
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